New drug combo targets Hard-to-Treat cancers
NCT ID NCT06074497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called KGX101, alone or with another drug (envafolimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. About 54 participants will take part in this open-label study across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, 3199, Australia
-
Pindara Private Hospital
Benowa, Queensland, 4217, Australia
-
Sunshine Coast University Private Hospital
Birtinya, Queensland, 4575, Australia